Skip to content
DataLookout
Menu

NodeSMARTNCT07085442

Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 23 versions: 22 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoint(s) modified
    • Eligibility criteria shortened, about 47 words
    • Study description expanded, about 3 words
  2. Notable Eligibility criteria shortened, about 14 words
    • Primary endpoints revised (20)
  3. Minor Study sites: 12 to 14
  4. Notable Eligibility criteria expanded, about 6 words
  5. Notable Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 15 of 25 entries
    • Site details revised at 1 of 12 sites
    • Study description expanded, about 1 word
  6. Notable Primary and study completion pushed from Dec 2032 to Dec 2033
    • Enrollment increased: 300 → 400 participants
    v18
  7. Notable Eligibility criteria expanded, about 34 wordsv17
  8. Notable Eligibility criteria expanded, about 25 wordsv16
  9. Notable Eligibility criteria expanded, about 1 word
    • Study description expanded, about 2 words
    v15
  10. Notable Eligibility criteria expanded, about 10 words
    • Study description expanded, about 10 words
    v13
  11. Notable Enrollment increased: 200 → 300 participantsv12
  12. Minor Study sites: 10 to 12v11
  13. Minor Study sites: 9 to 10v10
  14. Minor Study sites: 8 to 9v9
  15. Minor Study description expanded, about 23 wordsv8
  16. Notable Eligibility criteria expanded, about 85 words
    • Study sites: 7 to 8
    • Study description expanded, about 137 words
    v7
  17. Minor Study sites: 6 to 7v6
  18. Minor Study sites: 5 to 6v5
  19. Minor Study sites: 4 to 5v4
  20. Notable Primary and study completion dates: Dec 2030 to Dec 2032
    • Primary endpoints: 12 to 20
    • Study sites: 2 to 4
    • Secondary endpoints: 15 to 25
    v3
  21. Minor Study sites: 1 to 2v2
  22. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Patients with ≤2 nodal metastases identified on histology.
Timeframe: 12 months
Identification rate of marked node
Timeframe: 12 months
False negative rate of targeted sentinel node biopsy
Timeframe: 12 months
Arm lymphoedema
Timeframe: 12 months

Secondary (5)

Axillary recurrence
Regional (nodal) recurrence
Disease free survival
Overall survival
Local (breast or chest wall) recurrence

Arms and interventions

Patients with biopsy proven nodal metastases (cN1) and not receiving neoadjuvant chemotherapy

Patients with T1 or T2 tumours at presentation with biopsy proven nodal metastases (cN1) and with ≤2 abnormal nodes on axillary ultrasound

Procedures: Targeted Sentinel Node Biopsy (TSNB)

Sites

14 sites in 1 country